Proposal to Vitrolife AB Board Members

Dr. Madeleine Olsson has been nominated as a new member to the Board of Directors of Vitrolife AB (publ). Dr. Olsson, born in 1945, has been a doctor, specialising in gynaecology since 1984. She is engaged in the Queen Silvia Children’s Hospital Foundation (Stiftelsen för Drottning Silvias barn och ungdomssjukhus). Dr. Olsson owns 24.5 per cent of the shares in the Stena Group. Existing members of the Board of Directors Per Båtelson, Mark Dumenil, Prof. Lars Hamberger, Claes Glassell and Patrik Tigerschiöld have accepted nomination for re-election. Dr. Peter Svalander has declined re-election to the board. Dr. Svalander, whose two-year assignment as CEO of the company’s American subsidiary Vitrolife Inc. in Denver, Colorado draws to a close on 30 June 2004, will thereafter work in his own company as a training and research consultant in the field of IVF and cell cultivation. Vitrolife and Dr. Svalander look forward to continuing to work closely together from 1 July 2004. A change is proposed to the remuneration paid to the board from a total of SEK 240,000 per year to SEK 350,000 per year, of which SEK 100,000 would go to the Chairman of the Board and SEK 50,000 to each of the other Members. Shareholders representing approx. 37 per cent of the votes in the company, including Skanditek Industriförvaltning AB and Swedish Biotechnology AB, are supporting this proposal. For further information on the above, please contact: Patrik Tigerschiöld, Skanditek AB, Chairman of the Vitrolife Board +46 (0) 8-614 00 20 Gothenburg 21 April 2004 Vitrolife AB (publ) For further information, please contact; CEO: Dr. Magnus Nilsson Tel: +46 31 721 80 00 Mobile +46 708 22 80 61 mnilsson@vitrolife.com Acting CFO and IR agent: Anders Sävfält Tel: +46 31 721 80 00 asavfalt@vitrolife.com